

Federico Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1250366/publications.pdf>

Version: 2024-02-01

217
papers

6,476
citations

71061

41
h-index

88593

70
g-index

232
all docs

232
docs citations

232
times ranked

8665
citing authors

#	ARTICLE	IF	CITATIONS
1	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
2	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	4.6	345
3	Global and regional molecular epidemiology of HIV-1, 1990â€“2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 143-155.	4.6	255
4	Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. <i>Aids</i> , 1999, 13, F79-F86.	1.0	235
5	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 394-407.	4.6	218
6	A Dendritic Cellâ€“Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. <i>Science Translational Medicine</i> , 2013, 5, 166ra2.	5.8	193
7	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. <i>Aids</i> , 2001, 15, F29-F40.	1.0	160
8	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. <i>Drug Resistance Updates</i> , 2018, 37, 17-39.	6.5	155
9	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	2.9	135
10	Differential intestinal anti-inflammatory effects of <i>Lactobacillus fermentum</i> and <i>Lactobacillus salivarius</i> in DSS mouse colitis: impact on microRNAs expression and microbiota composition. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1700144.	1.5	135
11	ACCUMULATION OF METALS IN AUTOPSY TISSUES OF SUBJECTS LIVING IN TARRAGONA COUNTY, SPAIN. <i>Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering</i> , 2001, 36, 1767-1786.	0.9	99
12	Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Clinical Microbiology</i> , 2008, 46, 887-891.	1.8	98
13	Intestinal anti-inflammatory effect of the probiotic <i>Saccharomyces boulardii</i> in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. <i>Journal of Nutritional Biochemistry</i> , 2018, 61, 129-139.	1.9	98
14	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.	1.3	76
15	Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study. <i>BMC Cancer</i> , 2019, 19, 495.	1.1	75
16	Reviewing the Composition of Vaginal Microbiota: Inclusion of Nutrition and Probiotic Factors in the Maintenance of Eubiosis. <i>Nutrients</i> , 2020, 12, 419.	1.7	75
17	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018, 113, 1639-1648.	0.2	72
18	<i>Lactobacillus fermentum</i> Improves Tacrolimusâ€“Induced Hypertension by Restoring Vascular Redox State and Improving eNOS Coupling. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1800033.	1.5	71

#	ARTICLE	IF	CITATIONS
19	The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice. <i>Frontiers in Pharmacology</i> , 2018, 9, 468.	1.6	68
20	Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1006-1010.	1.3	64
21	Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota. <i>Nutrients</i> , 2019, 11, 337.	1.7	64
22	The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. <i>Journal of Virology</i> , 2011, 85, 11468-11478.	1.5	63
23	Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. <i>Aids</i> , 1999, 13, 1491-1496.	1.0	62
24	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.	1.4	62
25	Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2885-2888.	1.3	61
26	Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1948-1953.	1.3	61
27	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	1.7	60
28	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , 2016, 81, 82-89.	1.6	60
29	The metabolic and vascular protective effects of olive (<i>Olea europaea</i> L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties. <i>Pharmacological Research</i> , 2019, 150, 104487.	3.1	59
30	One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents. <i>Environmental Microbiology</i> , 2017, 19, 1536-1551.	1.8	54
31	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354.	2.9	53
32	<i>Lactobacillus reuteri</i> V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. <i>Nutrients</i> , 2019, 11, 1761.	1.7	53
33	Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey. <i>Lancet HIV</i> , 2020, 7, e772-e781.	2.1	51
34	Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009, 81, 763-767.	2.5	50
35	Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. <i>Aids</i> , 2013, 27, 1219-1229.	1.0	49
36	Pyrosequencing Analysis Reveals Changes in Intestinal Microbiota of Healthy Adults Who Received a Daily Dose of Immunomodulatory Probiotic Strains. <i>Nutrients</i> , 2015, 7, 3999-4015.	1.7	49

#	ARTICLE	IF	CITATIONS
37	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
38	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	1.0	45
39	Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. <i>Journal of Hepatology</i> , 2019, 71, 45-51.	1.8	45
40	Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects. <i>PLoS ONE</i> , 2011, 6, e19461.	1.1	45
41	Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1975-1981.	1.3	43
42	<i>Lactobacillus fermentum</i> CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis. <i>Pharmacological Research</i> , 2021, 167, 105471.	3.1	43
43	A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. <i>Aids</i> , 1999, 13, 2377-2388.	1.0	42
44	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	4.3	42
45	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015, 71, 571-577.	1.7	42
46	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. <i>AIDS Reviews</i> , 2010, 12, 135-48.	0.5	42
47	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naïve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. <i>Journal of Clinical Microbiology</i> , 2012, 50, 407-413.	1.8	41
48	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	4.6	41
49	The Immunomodulatory Properties of Propylpropane Thiosulfonate Contribute to its Intestinal Anti-inflammatory Effect in Experimental Colitis. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1800653.	1.5	40
50	Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 Å— 106/l. <i>Aids</i> , 1997, 11, 53-57.	1.0	39
51	Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. <i>Aids</i> , 2000, 14, 2485-2494.	1.0	39
52	Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing. <i>Clinical Infectious Diseases</i> , 2014, 59, 578-588.	2.9	38
53	Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS). <i>Antiviral Research</i> , 2011, 91, 150-153.	1.9	37
54	Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution. <i>British Journal of Pharmacology</i> , 2018, 175, 4353-4370.	2.7	36

#	ARTICLE	IF	CITATIONS
55	Sample pooling for SARS-CoV-2 RT-PCR screening. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1687.e1-1687.e5.	2.8	35
56	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. <i>AIDS Reviews</i> , 2012, 14, 208-17.	0.5	35
57	Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. <i>PLoS ONE</i> , 2016, 11, e0153754.	1.1	34
58	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. <i>BMC Infectious Diseases</i> , 2018, 18, 251.	1.3	33
59	Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232.	2.9	31
60	Residual Low-Level Viral Replication Could Explain Discrepancies between Viral Load and CD4+ Cell Response in Human Immunodeficiency Virus-Infected Patients Receiving Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2000, 30, 392-394.	2.9	30
61	The prebiotic properties of Hibiscus sabdariffa extract contribute to the beneficial effects in diet-induced obesity in mice. <i>Food Research International</i> , 2020, 127, 108722.	2.9	30
62	Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. <i>Antiviral Research</i> , 2010, 88, 281-286.	1.9	28
63	Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). <i>Journal of Infectious Diseases</i> , 2016, 213, 39-48.	1.9	28
64	Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the Tj ETQq0 0,0rgBT /Oyerlock 10	1.0	28
65	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017, 18, 225-235.	2.7	28
66	Polyarteritis nodosa confined to calf muscles. <i>Journal of Rheumatology</i> , 1992, 19, 303-5.	1.0	27
67	Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. <i>Clinical Microbiology and Infection</i> , 2012, 18, E485-E490.	2.8	26
68	Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers. <i>World Journal of Gastroenterology</i> , 2018, 24, 5223-5233.	1.4	26
69	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
70	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	2.0	26
71	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019, 42, 579-592.	0.2	25
72	Quantification of Viral Loads Lower than 50 Copies per Milliliter by Use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, Version 2.0, Can Predict the Likelihood of Subsequent Virological Rebound to >50 Copies per Milliliter. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1555-1557.	1.8	24

#	ARTICLE	IF	CITATIONS
73	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. <i>Journal of Infectious Diseases</i> , 1999, 179, 475-483.	1.9	23
74	Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy332.	0.4	23
75	Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections. <i>PLoS ONE</i> , 2019, 14, e0222439.	1.1	22
76	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS). <i>Antiviral Research</i> , 2011, 89, 19-25.	1.9	20
77	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. <i>Journal of Personalized Medicine</i> , 2021, 11, 475.	1.1	20
78	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 389-396.	0.1	20
79	Clinical spectrum of fever of intermediate duration in the south of Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 993-995.	1.3	19
80	Spatiotemporal Characteristics of the HIV-1 CRF02_AG/CRF63_02A1 Epidemic in Russia and Central Asia. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 415-420.	0.5	19
81	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1693-1700.	1.3	19
82	El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorar. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 231-238.	0.3	19
83	The Beneficial Effects of <i>Lippia Citriodora</i> Extract on Diet-Induced Obesity in Mice Are Associated with Modulation in the Gut Microbiota Composition. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e2000005.	1.5	19
84	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164.	0.5	18
85	Intestinal anti-inflammatory effects of probiotics in DSS-colitis via modulation of gut microbiota and microRNAs. <i>European Journal of Nutrition</i> , 2021, 60, 2537-2551.	1.8	18
86	Failure to bicitegravir and development of resistance mutations in an antiretroviral-experienced patient. <i>Antiviral Research</i> , 2020, 179, 104717.	1.9	18
87	Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations. <i>PLoS ONE</i> , 2014, 9, e90710.	1.1	17
88	Allium-Derived Compound Propyl Propane Thiosulfonate (PTSO) Attenuates Metabolic Alterations in Mice Fed a High-Fat Diet through Its Anti-Inflammatory and Prebiotic Properties. <i>Nutrients</i> , 2021, 13, 2595.	1.7	17
89	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1357-1362.	1.3	16
90	Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?. <i>Germs</i> , 2017, 7, 40-44.	0.5	16

#	ARTICLE	IF	CITATIONS
91	HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. <i>AIDS Reviews</i> , 2009, 11, 39-51.	0.5	16
92	Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2018, 41, 597-608.	0.2	15
93	G2-S16 sulfonate dendrimer as new therapy for treatment failure in HIV-1 entry inhibitors. <i>Nanomedicine</i> , 2019, 14, 1095-1107.	1.7	15
94	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 28-32.	0.3	15
95	Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 119-126.	0.3	15
96	Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 29-34.	0.8	14
97	Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelling by phylogenetic analysis. <i>PLoS ONE</i> , 2018, 13, e0201268.	1.1	14
98	Immunomodulatory tetracyclines ameliorate DNBS-colitis: Impact on microRNA expression and microbiota composition. <i>Biochemical Pharmacology</i> , 2018, 155, 524-536.	2.0	14
99	Effect of daily consumption of extra virgin olive oil on the lipid profile and microbiota of HIV-infected patients over 50 years of age. <i>Medicine (United States)</i> , 2019, 98, e17528.	0.4	14
100	Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. <i>Eurosurveillance</i> , 2019, 24, .	3.9	14
101	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.	1.0	13
102	Predicting antiretroviral drug resistance from the latest or the cumulative genotype. <i>Antiviral Therapy</i> , 2011, 16, 373-381.	0.6	13
103	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. <i>Clinical Microbiology and Infection</i> , 2018, 24, 540-545.	2.8	13
104	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018, 32, 327-335.	1.0	13
105	High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. <i>Journal of Hepatology</i> , 2019, 71, 876-888.	1.8	13
106	Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 235-241.	1.3	13
107	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	1.3	13
108	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	0.9	13

#	ARTICLE	IF	CITATIONS
109	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2857-2861.	1.3	12
110	Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1031-1038.	1.3	12
111	Post-exposure prophylaxis for HIV infection in sexual assault victims. <i>HIV Medicine</i> , 2020, 21, 43-52.	1.0	12
112	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	1.3	12
113	La simplificaci3n del proceso de diagn3stico de la hepatitis C cr3nica es una estrategia coste-efectiva. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2019, 37, 634-641.	0.3	12
114	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.1	12
115	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). <i>Clinical Microbiology and Infection</i> , 2015, 21, 105.e1-105.e5.	2.8	11
116	Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. <i>PLoS ONE</i> , 2019, 14, e0221231.	1.1	11
117	Diagn3stico tradicional versus diagn3stico en un solo paso del virus de la hepatitis C. Estudio piloto en 2 centros asistenciales. <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2019, 37, 348-349.	0.3	11
118	Introduction of HIV type 1 non-B subtypes into Eastern Andalusia through immigration. <i>Journal of Medical Virology</i> , 2003, 70, 10-13.	2.5	10
119	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiolog3a Cl3nica</i> , 2015, 33, 544-556.	0.3	10
120	Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission. <i>PLoS ONE</i> , 2020, 15, e0233528.	1.1	10
121	Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain. <i>Frontiers in Microbiology</i> , 2020, 11, 564486.	1.5	10
122	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
123	ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. <i>Clinical Microbiology and Infection</i> , 2022, 28, 812-822.	2.8	10
124	Relationship between viral genotype and viral load in patients with chronic hepatitis C. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 884-887.	1.3	9
125	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.	1.3	9
126	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. <i>Journal of Virus Eradication</i> , 2018, 4, 179-181.	0.3	9

#	ARTICLE	IF	CITATIONS
127	Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions. <i>Frontiers in Microbiology</i> , 2019, 10, 370.	1.5	9
128	Establishing a hepatitis C continuum of care among <scp>HIV</scp>/hepatitis C virusâ€‰coinfected individuals in Euro<scp>SIDA</scp>. <i>HIV Medicine</i> , 2019, 20, 264-273.	1.0	9
129	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2019, 37, 195-202.	0.3	9
130	Macrolide and fluoroquinolone resistance of <i>Mycoplasma genitalium</i> in southern Spain, 2018â€‰â€‰2019. <i>Sexually Transmitted Infections</i> , 2021, 97, 8-10.	0.8	9
131	The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 111, 10-16.	0.1	9
132	Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1738-1740.	1.3	9
133	Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.	1.4	8
134	Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 Å– 106/l. <i>Aids</i> , 2001, 15, 131-133.	1.0	8
135	Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 515-519.	0.1	8
136	The Antioxidant Activity of <i>Thymus serpyllum</i> Extract Protects against the Inflammatory State and Modulates Gut Dysbiosis in Diet-Induced Obesity in Mice. <i>Antioxidants</i> , 2022, 11, 1073.	2.2	8
137	Ten steps to eliminating hepatitis C in hospitals. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 481-483.	8.2	8
138	Detection of hepatitis A virus in wastewater. <i>Environmental Toxicology</i> , 1999, 14, 391-396.	2.1	7
139	Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1???Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 25, 26-35.	0.9	7
140	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68.	0.9	7
141	Improving Clinical Laboratory Efficiency: Introduction of Systems for the Diagnosis and Monitoring of HIV Infection. <i>The Open Virology Journal</i> , 2012, 5, 135-143.	1.8	7
142	Predictors of CD4+ T-Cell Counts of HIV Type 1â€‰Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
143	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. <i>Clinical Microbiology and Infection</i> , 2015, 21, 104.e1-104.e5.	2.8	7
144	High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach. <i>PLoS ONE</i> , 2017, 12, e0186928.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. <i>Journal of Hepatology</i> , 2019, 71, 1270-1272.	1.8	7
146	Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 127-131.	0.3	7
147	Phylogenetic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain. <i>PLoS ONE</i> , 2016, 11, e0168099.	1.1	7
148	Study of Different Systems for Interpreting Results of Genotypic Antiretroviral Drug Resistance Tests. <i>Antiviral Therapy</i> , 2003, 8, 251-252.	0.6	7
149	Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes. <i>Aids</i> , 2014, 28, 1835-1837.	1.0	6
150	Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing. <i>Scientific Reports</i> , 2019, 9, 9264.	1.6	6
151	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 314-320.	0.9	6
152	GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). <i>Journal of Infection</i> , 2020, 81, 600-606.	1.7	6
153	Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. <i>HIV Medicine</i> , 2021, 22, 674-681.	1.0	6
154	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naïve individuals: results from a European multi-cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2394-2399.	1.3	6
155	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. <i>Viruses</i> , 2021, 13, 1580.	1.5	6
156	Bacteria associated with periodontal disease are also increased in health. <i>Medicina Oral, Patología Oral Y Cirugía Bucal</i> , 2020, 25, e745-e751.	0.7	6
157	Levels of HSP70 in HIV+ patients in different viroimmunological states. <i>Journal of Medical Virology</i> , 2006, 78, 318-323.	2.5	5
158	Analysis of the quality of patient therapeutic education and information in a high complexity reference hospital. <i>Journal of Healthcare Quality Research</i> , 2018, 33, 343-351.	0.2	5
159	E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection. <i>Aids</i> , 2019, 33, 1613-1617.	1.0	5
160	Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. <i>Journal of Hepatology</i> , 2021, 75, 224-226.	1.8	5
161	Comparison between Aptima® assays (Hologic) and the CoBAS® 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> , and <i>Mycoplasma genitalium</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1337-1342.	1.3	5
162	The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. <i>PLoS ONE</i> , 2017, 12, e0175564.	1.1	5

#	ARTICLE	IF	CITATIONS
163	Unusual case report of skin infection by <i>Paenibacillus timonensis</i> . <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 139-140.	0.5	5
164	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. <i>Journal of Virus Eradication</i> , 2018, 4, 179-181.	0.3	5
165	Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. <i>HIV Medicine</i> , 2022, , .	1.0	5
166	Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure. <i>BMC Infectious Diseases</i> , 2016, 16, 197.	1.3	4
167	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
168	Spanish and Catalan translation, cultural adaptation and validation of the Picker Patient Experience Questionnaire-15. <i>Journal of Healthcare Quality Research</i> , 2018, 33, 10-17.	0.2	4
169	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. <i>Scientific Reports</i> , 2018, 8, 14905.	1.6	4
170	Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	4
171	Posición actual de la carga viral frente a la determinación de antígeno core del virus de la hepatitis C. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 12-18.	0.3	4
172	Serum hepatitis B virus DNA detection with S- and C-region-directed probes. <i>Journal of Medical Microbiology</i> , 1993, 39, 473-475.	0.7	4
173	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 112, 64-70.	0.1	4
174	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 580-587.	0.3	4
175	Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing. <i>AIDS Reviews</i> , 2017, 19, 231-238.	0.5	4
176	Use of deep sequencing data for routine analysis of HIV resistance in newly diagnosed patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19748.	1.2	3
177	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. <i>Annals of Hepatology</i> , 2019, 18, 236-239.	0.6	3
178	Long-term virological suppression on first-line efavirenz+tenofovir+emtricitabine/lamivudine for HIV-1. <i>Aids</i> , 2019, 33, 745-751.	1.0	3
179	Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1343-1349.	1.3	3
180	The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. <i>Viruses</i> , 2022, 14, 16.	1.5	3

#	ARTICLE	IF	CITATIONS
181	Retrospective analysis of antiretroviral HIV treatment success based on medical history or guided by the reverse hybridisation LiPA HIV genotyping system. <i>Journal of Medical Virology</i> , 2004, 73, 151-157.	2.5	2
182	Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19520.	1.2	2
183	Executive summary of the consensus document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 122-131.	0.3	2
184	Diagnosis of hepatitis C virus infection in Spain. On the correct side of the road?. <i>Journal of Hepatology</i> , 2018, 68, S173-S174.	1.8	2
185	The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 634-641.	0.2	2
186	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019, 42, 579-592.	0.0	2
187	Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy. <i>Sexually Transmitted Infections</i> , 2020, 96, 337-341.	0.8	2
188	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , 2021, 22, 218-224.	1.0	2
189	Visión microbiológica del impacto de la pandemia de COVID-19 sobre la eliminación de la hepatitis C. ¿Estamos preparados?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 475-476.	0.3	2
190	Pooling samples for hepatitis C RNA detection. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 608-609.	3.7	2
191	In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 95.	0.3	2
192	Highly accurate whole-genome imputation of SARS-CoV-2 from partial or low-quality sequences. <i>GigaScience</i> , 2021, 10, .	3.3	2
193	Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in South Eastern Spain (2005-2007). Detection of Minority Viral Quasispecies. <i>International Journal of Infectious Diseases</i> , 2008, 12, e157-e158.	1.5	1
194	Real life retreatment of patients failing DAAs in Spain: data from the HCVREsp cohort. <i>Journal of Hepatology</i> , 2017, 66, S313.	1.8	1
195	Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. <i>HIV Medicine</i> , 2017, 18, 482-489.	1.0	1
196	FRI-229-Reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective. <i>Journal of Hepatology</i> , 2019, 70, e495-e496.	1.8	1
197	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655.	1.3	1
198	Study of different systems for interpreting results of genotypic antiretroviral drug resistance tests. <i>Antiviral Therapy</i> , 2003, 8, 251-2.	0.6	1

#	ARTICLE	IF	CITATIONS
199	O5-6.1 Immunological response to hepatitis B vaccination in HIV infected patients: associated factors. Journal of Epidemiology and Community Health, 2011, 65, A56-A56.	2.0	0
200	A safe and easy method for building consensus HIV sequences from 454 massively parallel sequencing data. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2018, 36, 91-94.	0.2	0
201	Validación de un método seguro y sencillo para la elaboración de secuencias consenso del virus de la inmunodeficiencia humana a partir de los datos de secuenciación masiva 454. Enfermedades Infecciosas Y Microbiología Clínica, 2018, 36, 91-94.	0.3	0
202	PMD120 - HEALTHCARE OUTCOMES OF ONE-STEP DIAGNOSIS IN PATIENTS WITH CHRONIC HEPATITIS C. Value in Health, 2018, 21, S263.	0.1	0
203	THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment. Journal of Hepatology, 2019, 70, e219-e220.	1.8	0
204	THU-169-Genotype 4 RAS patterns in a European hepatitis C cohort. Journal of Hepatology, 2019, 70, e236.	1.8	0
205	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. Enfermedades Infecciosas Y Microbiología Clínica (English Ed) Tj ETQp1 0.784314 rgB	0.2	0
206	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. HIV Medicine, 2020, 21, 128-134.	1.0	0
207	In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2020, 38, 95.	0.2	0
208	Guide for the screening of HCV infection in Spain, 2020. Enfermedades Infecciosas Y Microbiología Clínica, 2021, 39, 527-528.	0.3	0
209	Hepatitis C reflex testing in Spain in 2019: A story of success. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2021, 39, 119-126.	0.2	0
210	Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy. Journal of Viral Hepatitis, 2021, 28, 878-886.	1.0	0
211	Impact of COVID-19 pandemic on hepatitis C elimination from the clinical microbiologist perspective. Are we ready?. Enfermedades Infecciosas Y Microbiología Clínica (English Ed), 2021, 39, 475-476.	0.2	0
212	Title is missing!. , 2020, 15, e0233528.		0
213	Title is missing!. , 2020, 15, e0233528.		0
214	Title is missing!. , 2020, 15, e0233528.		0
215	Title is missing!. , 2020, 15, e0233528.		0
216	Title is missing!. , 2020, 15, e0233528.		0

#	ARTICLE	IF	CITATIONS
217	HEPATITIS C VIRUS SCREENING AND LINKAGE TO CARE IN MENTAL HEALTH UNITS: AN OPPORTUNITY FOR HCV ELIMINATION.. Actas Espanolas De Psiquiatria, 2022, 50, 120-121.	0.1	0